1. HBW Insight
  2. >>Leadership

US FDA Restructuring May Be Next After Drugs Center Loses More Than 1,000 People

 
• By Derrick Gingery

The departure data emerged along with a Health and Human Services Department memo describing conceptual plans to consolidate and restructure offices at the FDA and other agencies.

HHS is considering plans to restructure the FDA and other agencies. (Shutterstock)
Key Takeaways
  • The Center for Drug Evaluation and Research lost more than 800 staff from the RIF, as well as another 200 from early retirements, buyouts and other departures.
  • Most departures came after the end of March, which surprised some in the agency.
  • An HHS memo also suggests plans are being developed to restructure the FDA, although they remain conceptual.

Layoffs, retirements and buyouts have cost the US Food and Drug Administration’s drug center more

Internal data obtained by the Pink Sheet indicate that the Center for Drug Evaluation and Research now has less than 5,000 employees after starting calendar year 2025 with 6,058, a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Leadership

People On The Move: Appointments At ANEPF, Inula, Opella

 
• By Tom Gallen

A round-up of the latest consumer health people moves: ANEFP elects president; Inula Group appoints CEO; Opella names ANZ head.

In Blistering Criticism, Health Subcommittee Democrat Warns Of Kennedy’s ‘Toxic Brew’ Plans

 
• By Malcolm Spicer

Trump’s first-term public health appointees “were serious people doing serious work in a bipartisan nature,” but HHS Secretary Robert F. Kennedy and other current presidential advisors “are not serious people,” says Massachusetts’ Jake Auchincloss.

MAHA Translates To ‘Change The Broken System’ At US FDA For Commissioner Makary

 
• By Malcolm Spicer

Among FDA's diversions from accepted practices is not going “through the bureaucracy” of advisory committees for experts’ input on potential changes to improve the safety and nutrition profile of food products, says Commissioner Martin Makary.

Commissioner Makary Outlines Expectations For US FDA: ‘Challenge Deeply Held Assumptions’

 
• By Malcolm Spicer

“It was a little hard to begin after the change or the reduction in force. We're doing everything we can to do an assessment, restore some services of individuals, and also try to rebuild the culture, because it is a great culture,” says FDA Commissioner Martin Makary during FDLI conference.

More from HBW Insight

Haleon Study: Boosting Health Literacy Could Save Major Economies Over $300bn Per Year

 
• By David Ridley

By addressing disparities in health literacy, particularly in the areas of oral care, bone health, nutrition and air pollution, the consumer health industry can “save lives and billions in healthcare costs, boosting productivity and increasing GDP,” says a new report from Haleon and Economist Impact.

J&J Plots Next Steps Following Third Failure To Resolve Talc Cases Through Bankruptcy

 
• By Lauren Nardella

After a Texas judge denied a bankruptcy plan, Johnson & Johnson attorneys plan to focus on debunking what they see as dubious scientific claims in civil court.

US FDA Supplement Office Chief Eyes ‘Movement’ This Year On NDI Notifications Final Guidance

 
• By Malcolm Spicer

“We've made some progress and really hope to see some movement as we move forward this year,” says FDA Office of Dietary Supplement Programs director Cara Welch.